Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease.

FH Durie, A Aruffo, J Ledbetter… - The Journal of …, 1994 - Am Soc Clin Investig
FH Durie, A Aruffo, J Ledbetter, KM Crassi, WR Green, LD Fast, RJ Noelle
The Journal of clinical investigation, 1994Am Soc Clin Investig
Chronic and acute graft-versus-host disease (cGVHD and aGVHD) result from donor cells
responding to host disparate MHC alleles. In cGVHD (H-2d--> H-2bd), heightened
polyclonal immunoglobulin production is due to the interaction of donor allospecific helper T
cells (Th) and the host B cells. In vivo administration of antibody to the ligand for CD40,
gp39, blocked cGVHD-induced serum anti-DNA autoantibodies, IgE production,
spontaneous immunoglobulin production in vitro, and associated splenomegaly. Antibody …
Chronic and acute graft-versus-host disease (cGVHD and aGVHD) result from donor cells responding to host disparate MHC alleles. In cGVHD (H-2d-->H-2bd), heightened polyclonal immunoglobulin production is due to the interaction of donor allospecific helper T cells (Th) and the host B cells. In vivo administration of antibody to the ligand for CD40, gp39, blocked cGVHD-induced serum anti-DNA autoantibodies, IgE production, spontaneous immunoglobulin production in vitro, and associated splenomegaly. Antibody production remained inhibited for extended periods of time after termination of anti-gp39 administration. Antiallogeneic CTL responses induced in a GVHD were also prevented by the in vivo administration of anti-gp39 as was the associated splenomegaly. These data suggest that CD40-gp39 interactions are critical in GVHD and that CD40-gp39 may be a valuable ligand-receptor pair for targeting immunotherapeutic agents to control GVHD.
The Journal of Clinical Investigation